PROGENICS PHARMACEUTICALS IN - COM (PGNX)

CUSIP: 743187106

Q4 2019 13F Holders as of 31 Dec 2019

Type / Class
Equity / COM
Total 13F shares
65,635,454
Share change
-2,330,809
Total reported value
$334,041,057
Put/Call ratio
153%
Price per share
$5.09
Number of holders
123
Value change
-$11,617,319
Number of buys
58
Number of sells
59

Quarterly Holders Quick Answers

What is CUSIP 743187106?
CUSIP 743187106 identifies PGNX - PROGENICS PHARMACEUTICALS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of PROGENICS PHARMACEUTICALS IN - COM (PGNX) as of Q4 2019

As of 31 Dec 2019, PROGENICS PHARMACEUTICALS IN - COM (PGNX) was held by 123 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 65,635,454 shares. The largest 10 holders included BlackRock Inc., FARALLON CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, EAGLE ASSET MANAGEMENT INC, STATE STREET CORP, CARILLON TOWER ADVISERS, INC., Broadfin Capital, LLC, GEODE CAPITAL MANAGEMENT, LLC, and NORTHERN TRUST CORP. This page lists 123 institutional shareholders reporting positions in this security for the Q4 2019 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.